Strong Protection by Bazedoxifene Against Chemically-Induced Ferroptotic Neuronal DeathIn Vitro and In Vivo

Xiangyu Hao, Bao Ting Zhu, Yifan Wang, Mingjie Hou, Yong Xiao Yang, Li‐Xi Liao, Tongxiang Chen, Pan Wang, Xiaojun ChenResearch Square 2024 · DOI

Abstract

Ferroptosis, a form of regulated cell death associated with iron-dependent lipid peroxidation, can be induced in cultured cells by chemicals such as erastin and RSL3. Protein disulfide isomerase (PDI) has been identified as a mediator of chemically-induced ferroptosis and a crucial target for protection. This study reports that bazedoxifene (BAZ), a selective estrogen receptor modulator, acts as an inhibitor of PDI and provides strong protection against ferroptosis in neuronal cells. BAZ directly binds to PDI, inhibiting its catalytic activity through a hydrogen bond with the His256 residue. This inhibition reduces iNOS and nNOS dimerization, nitric oxide (NO) accumulation, and cellular reactive oxygen species (ROS), including lipid-ROS. In vivo experiments demonstrate that BAZ protects mice against kainic acid-induced memory deficits and hippocampal damage, suggesting an estrogen receptor-independent, PDI-mediated neuroprotective mechanism.

Introduction: The Challenge of Ferroptosis

Ferroptosis is a regulated cell death pathway driven by iron-dependent lipid peroxidation. It is increasingly recognized as a significant factor in neurodegenerative diseases like Alzheimer’s and Parkinson’s, as well as ischemic injuries such as stroke. Consequently, identifying pharmacological inhibitors of ferroptosis is a high priority in neuropharmacology.

Bazedoxifene (BAZ) is an FDA-approved Selective Estrogen Receptor Modulator (SERM) currently used to treat postmenopausal osteoporosis. While SERMs have shown neuroprotective potential, the underlying molecular mechanisms—especially those independent of estrogen receptors—have remained unclear. This research investigates BAZ's ability to prevent ferroptosis by targeting specific cellular pathways.

Methodology and Target Identification

The study employed a multi-disciplinary approach, including in vitro cell biology, biophysical assays, computational modeling, and in vivo behavioral testing. Researchers used HT22 mouse hippocampal neuronal cells treated with erastin and RSL3 to model ferroptosis.

To confirm the molecular changes associated with ferroptosis and BAZ treatment at the transcriptional level, RT-qPCR was performed on key regulatory genes, including markers of lipid metabolism and antioxidant response.

Table of primer sequences used for RT-qPCR analysis of ferroptosis-related genes.

Target identification involved Surface Plasmon Resonance (SPR) and Cellular Thermal Shift Assays (CETSA) to characterize the binding between BAZ and PDI. Molecular docking and 100-ns Molecular Dynamics (MD) simulations were used to map the binding pocket, specifically identifying the role of the His256 residue.

Key Insights: A Novel Mechanism of Action

The study revealed that BAZ's neuroprotective effect is mediated through direct binding to Protein Disulfide Isomerase (PDI). While PDI typically assists in protein folding, under oxidative stress, it can facilitate cell death pathways.

  • The His256 Interaction: Simulations showed BAZ forms a critical hydrogen bond with PDI’s His256 residue. Mutating this residue (His256 to Ala256) abolished BAZ's inhibitory effect, confirming the binding site.
  • ER-Independent Protection: BAZ remained effective in cells lacking estrogen receptors (e.g., MDA-MB-231), proving the mechanism is distinct from its primary pharmacological use in bone health.
  • Disrupting the Toxic Cascade: By inhibiting PDI, BAZ prevents the dimerization of Nitric Oxide Synthase (NOS), thereby reducing toxic NO and lipid-ROS accumulation.

Results: Potent Neuroprotection

  • In Vitro Efficacy: BAZ achieved 100% protection against erastin-induced death at 500 nM and against RSL3-induced death at 125 nM.
  • High Binding Affinity: SPR assays calculated a $K_d$ of 3.3–3.6 nM for the BAZ-PDI interaction.
  • In Vivo Rescue: In a kainic acid-induced injury model, 3 mg/kg BAZ significantly improved working memory in mice, increasing Y-maze alternation rates from ~50% (random performance) to 65.5%.
  • Tissue Preservation: Histological analysis showed a dramatic reduction in degenerating neurons in the hippocampal CA3 region, from 124.3 ± 17.5 to 32.3 ± 8.7 per field.

Conclusion

Bazedoxifene emerges as a potent PDI inhibitor capable of halting ferroptosis in neurons. This discovery highlights an estrogen receptor-independent pathway for neuroprotection, positioning BAZ as a promising candidate for repurposing in the treatment of neurodegenerative disorders. Future research may explore the broader clinical implications of PDI inhibition, including its role in lipid metabolism and cholesterol management.

Summary updated

Abstract

<title>Abstract</title> Ferroptosis, a form of regulated cell death associated with iron-dependent lipid peroxidation, can be induced in cultured cells by chemicals (<italic>e.g.</italic>, erastin and RSL3). It has been shown that protein disulfide isomerase (PDI) is a mediator of chemically-induced ferroptosis and also a crucial target for ferroptosis protection. The present study reports that bazedoxifene (BAZ), a selective estrogen receptor modulator, is an inhibitor of PDI and can strongly protect against chemically-induced ferroptosis in neuronal cells. We find that BAZ can directly bind to PDI and inhibit its catalytic activity. Computational modeling analysis reveals that BAZ forms a hydrogen bond with PDI’s His256 residue. Inhibition of PDI by BAZ markedly reduces iNOS and nNOS dimerization and NO accumulation, and these effects of BAZ are associated with reductions in cellular ROS and lipid-ROS and protection against chemically-induced ferroptosis. In addition, the direct antioxidant activity of BAZ may also partially contribute to its protective effect against chemically-induced ferroptosis. <italic>In vivo</italic> animal experiments have shown that mice treated with BAZ are strongly protected against kainic acid-induced memory deficits and hippocampal neuronal damage. Together, these results demonstrate that BAZ is a potent inhibitor of PDI and can strongly protect against chemically-induced ferroptosis in hippocampal neurons both <italic>in vitro</italic> and <italic>in vivo</italic>. This work also provides evidence for an estrogen receptor-independent, PDI-mediated mechanism of neuroprotection by BAZ.
BibTeX
@inproceedings{hao2024strong,
  author = {Xiangyu Hao and Bao Ting Zhu and Yifan Wang and Mingjie Hou and Yong Xiao Yang and Li‐Xi Liao and Tongxiang Chen and Pan Wang and Xiaojun Chen},
  title = {{Strong Protection by Bazedoxifene Against Chemically-Induced Ferroptotic Neuronal DeathIn Vitro and In Vivo}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-4961621/v1},
}
Figure